GenePOC® launches its GenePOC® CDiff test in Canada
Debiopharm International SA and the Paul Scherrer Institute announce a licensing agreement for the development of a novel targeted radiotherapeutic…
The Japanese Cancer Association and Debiopharm Group Announce Winners of the 2018 JCA-Mauvernay Award
Le Challenge Debiopharm-Inartis récompense ses cinq finalistes 2018
FDA Grants Fast Track designation to Debiopharm International’s Debio 1347 for the treatment of patients with unresectable or metastatic tumors…
Kaiku Health raises €4.4 million series A financing to accelerate its digital therapeutics pipeline led by Debiopharm and Tesi
Challenge Qualité de vie du patient 2018 : l’appel à projets est ouvert !
GenePOC launches its revogene™ instrument and GBS LB test in Canada
Debiopharm continues the fight against antibiotic resistance with investment in ABAC Therapeutics Inc.